Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News Analysis
Nature Reviews Drug Discovery 7, 631–632 (1 August 2008) | doi:10.1038/nrd2648
Pharma pursues novel models for academic collaboration
Abstract
Since early June this year, there has been a flurry of announcements from pharmaceutical companies embarking on collaborations with academic institutions. GlaxoSmithKline (GSK), for example, has teamed up with the Immune Disease Institute, Boston, USA, aiming to become a world leader in immuno–inflammatory drug discovery; AstraZeneca will work with Columbia University Medical Center, New York, USA, to develop novel therapeutics for diabetes and obesity; and Pfizer aims to advance drug discovery across many therapeutic areas with the University of California in San Francisco (UCSF), USA.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
